CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer...
Phase 2
Charlotte, North Carolina, United States and 135 other locations
PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors...
Phase 1
Huntersville, North Carolina, United States of America and 4 other locations
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma whic...
Phase 3
Charlotte, North Carolina, United States and 38 other locations
(with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzaluta...
Phase 1, Phase 2
Huntersville, North Carolina, United States of America and 30 other locations
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2....
Phase 1
Charlotte, North Carolina, United States and 19 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
Huntersville, North Carolina, United States of America and 16 other locations
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...
Phase 2
Charlotte, North Carolina, United States and 122 other locations
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors...
Phase 1, Phase 2
Huntersville, North Carolina, United States of America and 7 other locations
and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors...
Phase 1
Huntersville, North Carolina, United States of America and 14 other locations
targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors...
Phase 1
Charlotte, North Carolina, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal